1. Home
  2. TIL vs HIT Comparison

TIL vs HIT Comparison

Compare TIL & HIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • HIT
  • Stock Information
  • Founded
  • TIL 2018
  • HIT 1964
  • Country
  • TIL United States
  • HIT United States
  • Employees
  • TIL N/A
  • HIT N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • HIT Specialty Insurers
  • Sector
  • TIL Health Care
  • HIT Finance
  • Exchange
  • TIL Nasdaq
  • HIT Nasdaq
  • Market Cap
  • TIL 177.1M
  • HIT 152.4M
  • IPO Year
  • TIL 2021
  • HIT 2024
  • Fundamental
  • Price
  • TIL $12.74
  • HIT $1.44
  • Analyst Decision
  • TIL Strong Buy
  • HIT Strong Buy
  • Analyst Count
  • TIL 5
  • HIT 1
  • Target Price
  • TIL $100.67
  • HIT $2.50
  • AVG Volume (30 Days)
  • TIL 62.5K
  • HIT 466.5K
  • Earning Date
  • TIL 11-13-2025
  • HIT 11-10-2025
  • Dividend Yield
  • TIL N/A
  • HIT N/A
  • EPS Growth
  • TIL N/A
  • HIT N/A
  • EPS
  • TIL N/A
  • HIT 0.02
  • Revenue
  • TIL N/A
  • HIT $30,723,490.00
  • Revenue This Year
  • TIL N/A
  • HIT $70.02
  • Revenue Next Year
  • TIL N/A
  • HIT $63.39
  • P/E Ratio
  • TIL N/A
  • HIT $65.25
  • Revenue Growth
  • TIL N/A
  • HIT 55.15
  • 52 Week Low
  • TIL $10.80
  • HIT $0.51
  • 52 Week High
  • TIL $42.79
  • HIT $7.59
  • Technical
  • Relative Strength Index (RSI)
  • TIL 31.33
  • HIT 27.64
  • Support Level
  • TIL $13.53
  • HIT $1.49
  • Resistance Level
  • TIL $16.00
  • HIT $3.05
  • Average True Range (ATR)
  • TIL 1.32
  • HIT 0.34
  • MACD
  • TIL -0.22
  • HIT -0.14
  • Stochastic Oscillator
  • TIL 7.95
  • HIT 3.99

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

Share on Social Networks: